Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 6.000-6.400 for the period, compared to the consensus EPS estimate of 5.970. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $74.94 on Thursday. Halozyme Therapeutics has a 1 year low of $42.01 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company’s 50-day moving average is $69.97 and its 200 day moving average is $61.86. The stock has a market capitalization of $8.77 billion, a P/E ratio of 17.15, a P/E/G ratio of 0.40 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. During the same quarter in the previous year, the company earned $0.91 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, sell-side analysts expect that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HALO shares. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Morgan Stanley lifted their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, August 18th. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Finally, Benchmark lifted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $69.89.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director owned 46,952 shares in the company, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 88,227 shares of company stock worth $6,020,595 over the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HALO. EverSource Wealth Advisors LLC raised its position in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $195,000. Daiwa Securities Group Inc. raised its position in shares of Halozyme Therapeutics by 919.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,025 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 3,630 shares during the period. Optimist Retirement Group LLC bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $292,000. Finally, Diversify Advisory Services LLC raised its position in shares of Halozyme Therapeutics by 11.7% during the 2nd quarter. Diversify Advisory Services LLC now owns 6,929 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 727 shares during the period. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.